Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Profit After Tax of -$27.0 million for Q1 2026, up 7.27% on a QoQ basis from -$29.1 million in Q4 2025, and down 91.56% year-over-year from -$319.5 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Profit After Tax history runs 9 years deep, the most recent figure standing at -$27.0 million for Q1 2026.
- Quarterly Profit After Tax fell 91.56% year-over-year to -$27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.7 million (down 15.35% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.73% from the prior year.
- Profit After Tax was -$27.0 million for Q1 2026 at Arcturus Therapeutics Holdings, up from -$29.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at $117.3 million in Q4 2022 and bottomed at -$52.6 million in Q2 2023.
- A 5-year average of -$11.4 million and a median of -$17.2 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 403.51% — and 2024, when it slumped 156.3%.
- Arcturus Therapeutics Holdings' Profit After Tax stood at $117.3 million in 2022, then sank by 109.98% to -$11.7 million in 2023, then tumbled by 156.3% to -$30.0 million in 2024, then advanced by 3.09% to -$29.1 million in 2025, then climbed by 7.27% to -$27.0 million in 2026.
- Business Quant data shows ARCT's Profit After Tax at -$27.0 million in Q1 2026, -$29.1 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -26.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.96 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.22 Mn |
| Jun 30, 2023 | -52.55 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 117.35 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.17 Mn |
| Dec 31, 2021 | -38.66 Mn |
| Sep 30, 2021 | -54.08 Mn |
| Jun 30, 2021 | -54.58 Mn |